by DrKSSMDPhD | March 24, 2015 8:07 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2015/03/the-great-gallic-foie-gras-hack/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
Kenney had referenced an article in SA by Bret Jensen: “I have been selling some out of money calls on some of my positions in these small biotech stocks that have had substantial run ups over the past year since the end of the first quarter. I would also confine any new money for buying any dips primarily to those large cap “safe” biotech stocks with visible earnings streams and reasonable valuations that I profiled earlier in the week.” I have mentioned doing the same before, and it is based on where the market is going. I think we will have a longer gradual decline in the market, with biotech falling after the DOW. I view Monday as a blip, perhaps CLDN caused as Dr KSS commented, but not part of a larger decline. I would still buy good bios, but move towards those you can option with out of the money covered calls to help protect your basis. Puts would be better in a rapidly falling market. If the markef goes up then you may loose some good stocks. I thought of doing this to ESPR, but I don’t want to loose out on price appreciation, so no covered calls on that one, but CELG and GILD are good ones to cover IMHO.
Praise the Lord we have great guidance and a new article here:
http://www.stockgumshoe.com/2015/04/abiding-ambiguity-achaogen-and-arrowhead/
Thank you so very much Dr. KSS. Best2ALL!-Benjamin
“And there was much rejoicing.”
I found this discusssion site and was very impressed with the writings of Dr. KSS…. May I offer an update on GNFTF from the Schwab website:
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
4:10 PM ET, 07/09/2021 – GlobeNewswire
Lille, France;Cambridge, MA; July09, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2021:
105,050 shares€646 510.51
During the first half of 2021, total trading was:
On the buy side: 1,013,138 shares for a total amount of €4,450,737.46On the sell side: 997,017 shares for a total amount of €4,409,259.22
During this same period, the number of trades were:
On the buy side: 1,926On the sell side: 1,901
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:
27, 911 shares€769 849,43
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4®, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. In January 2019, GENFIT signed a licensing agreement with Labcorp® to make NIS4® technology available for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT signed another licensing agreement with Labcorp® to commercialize NIS4® in the US and Canada as a Laboratory Developed Test. Since April 2021, Labcorp® has commercialized NASHnext™, powered by NIS4®, for use in the clinic. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) test supported by NIS4® technology. For more information, please visit: https://nis4.com. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). http://www.genfit.com
CONTACT
GENFIT | Investors
Tel: +1 (617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Stephanie BOYER – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com